
The Prototype: King Tut's Curse Might Kill Leukemia
In this week's edition of The Prototype, we look at cancer-killing fungi, robots that perform surgery on your eyeballs, genetically modified bacteria that turn plastic into Tylenol and more. You can sign up to get The Prototype in your inbox here .
Getty Images
W hen I was a kid, I was obsessed with King Tut's tomb–and the legends of the curse put upon the team that discovered it. Of course, the stories were false and many of the tomb's discoverers lived long lives after finding it. But King Tut may have claimed at least one victim, Lord Carnarvon, thanks to a toxic fungus called aspergillus that had lain dormant for centuries.
Now that 'curse' may be hitting a different target–leukemia. A new study published this week found that chemical compounds in aspergillus, when purified, show anti-cancer properties. And if a fatty molecule is added to the purified fungus the resulting compound demonstrates cancer-fighting activity similar to that of drugs currently used to treat leukemia.
Next up, the scientists plan to take the most promising chemical candidates and test them on cancer in animals. If successful there, the chemicals could one day be used to treat human cancer patients.
Forsight Robotics
C ataract surgery is one of the world's most common medical procedures, with more than 4 million of them done each year in the United States alone, but there simply aren't enough doctors available to meet the demand for everyone who needs the surgery. An Israeli startup is betting that robots can someday easy that demand by doing the procedure better and cheaper than human doctors.
ForSight Robotics on Tuesday said it had raised $125 million led by Eclipse Ventures to expand Oryom, its robotic surgery platform for cataracts and other eye diseases . The funding is the second-largest Series B investment in a surgical robotics startup, and brings ForSight's total investment to $195 million. The new money values the company at an estimated $500 million—a substantial increase since it last raised funds in 2022 at a $162 million valuation, according to VC database PitchBook. Additional investors include Fred Moll, the cofounder of Intuitive Surgical and pioneer of robotic surgery, who has joined the company's strategic advisory board.
ForSight has been testing its robot on pig eyes, and plans to complete its first full robotic surgery on a human patient later this year. It's targeting the U.S. market and is in early conversations with the FDA. While ForSight's robots would be the first for cataracts, robotic surgery has become increasingly commonplace since $185 billion (market cap) Intuitive Surgical received FDA approval for its Da Vinci robots, which enable precision procedures, 25 years ago.
'At first people were intimidated by robotics' advancement,' Dr. Joseph Nathan, ForSight's cofounder, president and chief medical officer, told Forbes. 'Now they are seeing robotics as the thing that will get them the best outcomes.'
Read the whole story at Forbes DISCOVERY OF THE WEEK: TURNING PLASTIC INTO PAINKILLERS
Researchers at the University of Edinburgh have genetically engineered a bacteria that can take waste plastic and turn it into an ingredient used in acetaminophen (aka Tylenol). To make this work, they chemically broke down PET, a common plastic used in food packaging, into a simpler molecule and added it to a cell culture. The bacteria then produced special enzymes that interacted with the plastic molecule, transforming it into the painkiller ingredient. The researchers found that over 90% of the plastic was transformed into the drug, and the process used less energy than the conventional way to produce it from crude oil. The team's next step is to develop a way to scale the process to provide a more sustainable way to manufacture acetaminophen, with the backing of pharmaceutical companies like AstraZeneca. FINAL FRONTIER: FIRST PHOTOS FROM VERA RUBIN OBSERVATORY
The Vera C. Rubin observatory, a giant telescope built in the mountains of Chile, released its first images of space this week. The observatory used a $168 million car-size digital camera tag of –paired with a unique three-mirror telescope to not only capture the unprecedentedly high-resolution images of a cluster of galaxies in the constellation Virgo, but also monitor changes in that part of the sky thanks to its ability to record time-lapsed videos. WHAT ELSE I WROTE THIS WEEK
In my other newsletter, InnovationRx, Amy Feldman and I looked at health insurance companies promising to improve the prior authorization process (again), how Bell Labs plans to commercialize its massive IP portfolio, American attitudes towards vaccinating kids, and more. SCIENCE AND TECH TIDBITS
NASA's James Webb Space Telescope has discovered its first planet outside the solar system. About the size of Saturn, the new world is circling a red dwarf star about 111 light-years away.
Self-driving taxi company Waymo has begun operating in Atlanta, marking the fifth major U.S. city its services are available in.
The Trump administration has terminated millions of dollars of government subscriptions to the Springer Nature group, which publishes major scientific journals such as Nature .
After months of delays, SpaceX launched its fourth mission with Axiom Space, sending four astronauts to the International Space Station where they will conduct a wide variety of scientific experiments for Axiom's customers. PRO SCIENCE TIP: MAKE YOUR BUSINESS MORE PROFITABLE WITH AN IPO
A new study of the brains of mice suggests that one of the best ways to learn a new task is to devote time to not learning it. The researchers found that mice learned more quickly when they were allowed to explore new environments without focusing on any particular task. Evidently areas of the brain developed during unstructured activities can help expedite the completion of specific tasks. If that holds true in humans, it may be a good idea to stay productive by making sure you take the time to be unproductive. WHAT'S ENTERTAINING ME THIS WEEK
I recently finished the novel The Book Censor's Library by Bothayna Al-Essa. It's set in a dystopian future where censorship is the norm. The story follows the titular censor, who in his ambition to be good in his new job finds himself falling in love with reading. That leads him to a resistance movement, where he struggles to protect both books and his own daughter, who displays far more imagination than society will allow. MORE FROM FORBES Forbes Elon Musk Has Fired One Of His Top Tesla Lieutenants By Alan Ohnsman Forbes Why The U.S. Should Copy Canada To Fix Its Broken Air Traffic Control System By Jeremy Bogaisky Forbes The 36 Colleges Most At Risk From Pell Grant Cuts By Fiona Riley
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Washington Post
13 minutes ago
- Washington Post
How to protect yourself from ticks year-round
WASHINGTON — Ticks can be active in any season and it's important to check for and remove the bloodsuckers as quickly as possible — especially after you've been outside hiking, gardening or enjoying nature. 'Humans are outside more in summer so we hear about more tick infections ,' said Sam Telford, an infectious diseases expert at Tufts University. But he urges caution year-round because 'every season is tick season.'


Bloomberg
16 minutes ago
- Bloomberg
Wind, Solar Credits Face Shorter Phase-Out in GOP's New Tax Bill
Key tax incentives for US wind and solar projects would face a more aggressive phase-out in the Senate's latest version of President Donald Trump's spending package. The tweak, which follows pushback by Trump on the Inflation Reduction Act credits, would sharply limit the number of solar and wind farms that qualify for incentives, appeasing opponents while risking the ire of moderate members who argued for a slower phase-out.
Yahoo
18 minutes ago
- Yahoo
Can PayPal Stock Hit $125 in 2025?
Digital payment giant PayPal's (PYPL) story has been anything but smooth. After soaring in 2020 and carrying the momentum into early 2021, PYPL stock stumbled, ending three consecutive years in the red. While 2024 brought a much-needed rebound, 2025 has seen shares slip once again. Much of PayPal's decline can be traced to rising competition. Newer, faster fintech rivals have outpaced the company with sleeker, more intuitive payment solutions. Still, PayPal isn't going down without a fight. In response, PayPal brought in CEO Alex Chriss in 2023 to reset its strategy. Under his leadership, the company has launched features like one-click and express checkout while sharpening its focus on profitable growth and operational efficiency. Dear Nvidia Stock Fans, Watch This Event Today Closely A $2 Billion Reason to Sell Super Micro Computer Stock Now 3 ETFs Offering Juicy Dividend Yields of 15% or Higher Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! PayPal's ever-expanding partner network — featuring giants such as Amazon (AMZN), Shopify (SHOP), Apple (AAPL), Alphabet (GOOGL), and Meta Platforms (META) — also remains a powerful asset. With Wall Street's highest target pegged at $125 for the stock, can PayPal rally hard enough to hit that mark before the year wraps? PayPal runs a global technology platform that connects merchants and consumers through a dynamic two-sided network. Whether shopping online or in-person, users can pay, get paid, transfer, or withdraw funds using a wide range of options, including bank accounts and cards, PayPal and Venmo balances, cryptocurrency, and more — making digital payments seamless and accessible worldwide. With its market capitalization currently hovering around $71 billion, PayPal remains a major player in the fintech space. However, its stock performance tells a different story. Delivering a 25% return over the past one year, the stock has taken a 14% hit so far in 2025, underperforming the broader S&P 500 Index ($SPX) by a wide margin, with the benchmark up 4.4% year-to-date (YTD). PYPL stock touched a YTD high of $93.25 in January but has since fallen more than 21% from that peak. Considering its sluggish price action, PayPal now appears to be a potential value play. The stock is trading at just 14 times forward earnings and 2.25 times sales, which is significantly below its five-year averages. For investors hunting for discounted fintech names, PayPal's current valuation could offer an attractive entry point. PayPal delivered its fiscal 2025 first-quarter earnings on April 29. The results were a mixed bag, showing a slight revenue miss but a strong profit beat. Sales rose just 1% year-over-year (YOY) to $7.8 billion, falling short of expectations. However, the company made it clear this was by design. PayPal emphasized its strategic pivot toward profitability, deliberately phasing out lower-margin revenue streams. That shift paid off on the bottom line. Adjusted EPS came in at $1.33, up 23% from a year ago and beating Wall Street estimates by an impressive 15.7% margin. PayPal continued to strengthen its financial footing in Q1, with transaction margin dollars — the company's core profitability metric — rising 7% to $3.7 billion. Active accounts grew 2% YOY to reach 436 million, reflecting steady user engagement. Backed by a strong balance sheet with $15.8 billion in cash, cash equivalents, and investments, PayPal also returned $1.5 billion to shareholders through share repurchases, underscoring its commitment to capital returns. Reflecting on the Q1 performance, Chriss noted, 'PayPal had a great start to the year and our strategy is working. This is our fifth consecutive quarter of profitable growth with progress across branded checkout, PSP, omnichannel, and Venmo.' Looking ahead, PayPal offered a dose of optimism with strong Q2 guidance, projecting adjusted EPS between $1.29 and $1.31, signaling continued momentum on the profitability front. For the full year, the company took a more cautious stance. Citing ongoing global macroeconomic uncertainty, PayPal reaffirmed its earlier guidance, expecting full-year EPS to land between $4.95 and $5.10. By comparison, analysts tracking PayPal project the company's profit to grow 9.3% annually to $5.08 per share in fiscal 2025, followed by an even stronger 11% rise to $5.64 in fiscal 2026. Overall, Wall Street sentiment toward PYPL stock remains cautiously upbeat, with analysts giving it a consensus 'Moderate Buy' rating. Of the 44 analysts offering recommendations, 16 give it a solid 'Strong Buy" rating, two suggest a 'Moderate Buy,' 22 give a 'Hold,' and the remaining four advocate for a 'Strong Sell" rating. PYPL stock's average analyst price target of $79.81 indicates 9% potential upside. But the Street-high target of $125 tells a more bullish story, implying a potential rally of 70% if the company's turnaround strategy hits its stride. On the date of publication, Anushka Mukherji did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on